Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight Cuts Additional 20 Percent of Staff as Restructuring Heats Up

NEW YORK, Nov. 21 - Two weeks after being delisted from the Nasdaq exchange, Pharsight said it will dismiss 20 percent of its staff and cut second-tier products and services.

 

Pharsight said the move, designed to shift more attention to its core products and services, was devised to save the company between $2 million and $2.5 million a year. The firm, which will incur a one-time charge of $200,000 in the fourth quarter for the action, took similar steps four months ago when it laid off 15 percent of its workforce as one component in a broader plan to save $3 million per year.

 

It was not immediately clear how many people 20 percent represents, or what resources it defines as "not integral." Pharsight says on it web site that it currently employs more than 100 people in its base in Mountain View, Calif., and in offices in London; Cary, NC; Lexington, Mass.; and San Francisco. Officials from Pharsight did not return telephone calls seeking comment.

 

In a statement, Pharsight president and CEO said: "We trust that our increased concentration on our core offerings and continued control over spending will strengthen the foundation for Pharsight's future growth and profitability."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.